Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:3
  • preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 1 od 1  
2008, vol. 58, br. 5-6, str. 432-442
Farmaceutsko-tehnološki aspekti savremenih kardiovaskularnih lekova
Univerzitet u Beogradu, Farmaceutski fakultet, Institut za farmaceutsku tehnologiju i kozmetologiju
Sažetak
Savremen farmaceutsko-tehnološki pristup formulaciji preparata u terapiji kardiovaskularnih oboljenja vezan je, pre svega, za individualizaciju i racionalizaciju terapije uz obezbeđenje dobre prihvatljivosti od strane pacijenta i smanjenje neželjenih efekata. U skladu sa tim, novine u formulaciji farmaceutskih oblika sa kardiovaskularnim lekovima odnose se, uglavnom, na razvoj novih, 'naprednih' terapijskih sistema, tj. preparata sa modifikovanim oslobađanjem lekovite supstance. U radu je dat je pregled tehnologija zastupljenih u komercijalno dostupnim preparatima koji se koriste u terapiji kardiovaskularnih oboljenja, s posebnim osvrtom na tablete/kapsule sa modifikovanim oslobađanjem, višečestične terapijske sisteme, preparate sa pulsnim oslobađanjem lekovite supstance i OrosTM terapijske sisteme.
Reference
*** (2006) European Pharmacopoeia. Strasbourg: Council of Europe, 6th edition
Agencija za lekove i medicinska sredstva Srbije (2008) Nacionalni registar lekova. Beograd
Aulton, M.E., ur. (2002) Pharmaceutics: The Science of Dosage Form Design. London: Churchill Livingstone
Charman, S.A., Charman, W.N. (2003) Oral modified-release systems. u: Rathbone M.J., Hadgraft J., Roberts M.S. [ur.] Modified-Release Drug Delivery Technology, New York: Marcel Dekker
Conte, U., Maggi, L. (2000) A flexible technology for the linear, pulsatile and delayed release of drugs, allowing for easy accommodation of difficult in vitro targets. J Control Release, 64(1-3): 263-8
Cutler, N.R., Anders, R.J., Jhee, S.S., Sramek, J.J., Awan, N.A., Bultas, J., Lahiri, A., Woroszylska, M. (1995) Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. Am J Cardiol, 75(16): 1102-6
Epstein, M. (1997) The calcium antagonist controversy: The emerging importance of drug formulation as a determinant of risk. Am J Cardiol, 79(10A): 9-19; disc
Frishman, W.H., Glasser, S., Stone, P., Deedwania, P.C., Johnson, M., Fakouhi, T.D. (1999) Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol, 83(4): 507-14
Ghebre-Selassie, I., ur. (1994) Multiparticulate oral drug delivery. New York: Marcel Dekker
Hermida, R.C., Ayala, D.E., Calvo, C., i dr. (2007) Chronotherapy of hypertension: Administration-time-dependent effects of treatment on the circadian patters of blood pressure. Advanced Drug Delivery Reviews, 59(9-10): 923
Kažić, T.M. (2004) Kardiovaskularni lekovi - priručnik za terapiju. Beograd: Integra
Kleinbloesem, C.H., van Brummelen, P., Danhof, M., Faber, H., Urquhart, J., Breimer, D.D. (1987) Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther, 41(1): 26-30
Kydonieus, A., ur. (1992) Treatase of controlled drug delivery. New York: Marcel Dekker
Maroni, A., Zema, L., Cerea, M., Sangalli, M.E. (2005) Oral pulsatile drug delivery systems. Expert Opinion on Drug Delivery, 2(5): 855
Messerli, F.H. (1996) What, if anything, is controversial about calcium antagonists?. Am J Hypertens, 9(12 Pt 2): 177S-181S
Murdoch, D., Brogden, R.N. (1991) Sustained release nifedipine formulations: An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders. Drugs, 41(5): 737-79
Ostojić, M.Č., i dr. (2002) Preporuke za prevenciju ishemijske bolesti srca - nacionalni vodič kliničke prakse. Beograd: Ministarstvo zdravlja RS - Nacionalni komitet za izradu vodiča kliničke prakse u Srbiji
Sica, D. (2006) Secondary prevention to acute myocardial infarction: Managing the disease and the patient. American Journal of Cardiology, 98 (7) Suppl 1: 1-4
Silvestry, F.E., st John, S.M.G. (1998) Sustained-release calcium channel antagonists in cardiovascular disease: Pharmacology and current therapeutic use. Eur Heart J, 19 Suppl I: I8-14
Smith, D.H., Neutel, J.M., Weber, M.A. (2001) A new chronotherapeutic oral drug absorption system for verapamil optimizes blood pressure control in the morning. Am J Hypertens, 14(1): 14-9
Stevens, H.N.E., Wilson, C.G., Welling, P.G., Bakhshaee, M., Binns, J.S., Perkins, A.C., Frier, M., Blackshaw, E.P., Frame, M.W., Nichols, D.J., Humphrey, M.J., Wicks, S.R. (2002) Evaluation of Pulsincap to provide regional delivery of dofetilide to the human GI tract. Int J Pharm, 236(1-2): 27-34
Urquhart, J. (2000) Internal medicine in the 21st century: Controlled drug delivery: therapeutic and pharmacological aspects. J Intern Med, 248(5): 357-76
Wise, D.L., ur. (2000) Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker Inc
Wong, P.S.L., Gupta, S.K., Stewart, B.E. (2003) Osmotically controlled tablets. u: Rathbone M.J., Hadgraft J., Roberts M.S. [ur.] Modified-Release Drug Delivery Technology, New York: Marcel Dekker Inc, str. 101-114
 

O članku

jezik rada: srpski
vrsta rada: stručni članak
objavljen u SCIndeksu: 01.12.2008.